{
  "report_rows": [
    {
      "kpi": "Q2 2026 adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$3.09 vs. cons $3.01",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 total reported revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.648B vs. cons $1.620B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 legacy organic constant-currency growth",
      "prediction": "BEAT",
      "answer": "pred ~8.2% vs. cons 7.0%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Total reported revenue",
      "prediction": "BETTER",
      "answer": "guide ~$6.47B vs. cons $6.44B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BETTER",
      "answer": "guide ~$14.60 vs. cons $14.50 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BETTER",
      "answer": "guide ~$3.95 vs. cons $3.91 (Q3 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 4.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.0,
  "day5_path": "FADE",
  "day5_rationale": "A Q2 beat and modest FY2026 raise should lift the shares initially, but guide ~$14.60 vs. cons $14.50 leaves implied H2 adjusted EPS of only ~$8.81 vs. cons ~$8.79 after the predicted Q2 beat, limiting subsequent estimate revisions.",
  "day5_confidence": "MEDIUM"
}